This is a working overview of GHRH receptor, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-05-10 and is reviewed periodically as new material appears.
CJC-1295 is a synthetic peptide designed as a long-acting analogue of growth hormone-releasing hormone (GHRH). Its structure derives from the first 29 amino acids of native GHRH, a fragment often called GRF(1-29). Four substitutions were introduced to slow enzymatic breakdown and extend activity relative to the natural sequence. The compound was developed by ConjuChem as part of a broader effort to improve the pharmacokinetic profile of peptide hormones. It is studied in laboratory and clinical research settings rather than appearing as a naturally occurring substance.
Two related forms circulate in technical discussion under the same family name. The original version carries a drug affinity complex (DAC) that binds covalently to serum albumin after administration, and this linkage substantially extends circulation time. A second form, frequently written as modified GRF(1-29) or CJC-1295 without DAC, lacks that linker and clears much faster. The naming is a frequent source of confusion because the shorthand CJC-1295 can refer to either form depending on the source. Reports sometimes fail to specify which variant was studied.
The peptide backbone includes a D-alanine at position two, which resists cleavage by dipeptidyl peptidase IV, and several other substitutions that reduce degradation. Its molecular weight is roughly 3.4 kDa without the linker and about 3.6 kDa with it. The molecule is water soluble and is normally supplied as a lyophilized powder. Precise sequence and mass values depend on which variant is described, so technical documents usually state the exact form being referenced.
CJC-1295 belongs to a family of synthetic peptides modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. The compound is built from the first twenty-nine amino acids of the natural human sequence, a fragment that retains full receptor binding capacity. Native growth hormone-releasing hormone is degraded quickly in circulation, so the fragment alone has limited practical value. Early work therefore focused on chemical modifications that preserve receptor binding while slowing enzymatic breakdown. The result is a molecule described in the literature as a long-acting analog of the natural hormone.
Two forms circulate under the CJC-1295 name, and they differ by a single appended group. The version without a drug affinity complex carries four substitutions along the peptide chain, including a D-alanine near the amino terminus and replacements at three other positions. These changes block the enzyme dipeptidyl peptidase IV and remove a methionine residue that is prone to oxidation. The modified fragment is frequently labeled MOD GRF 1-29. Naming conventions are inconsistent across informal sources, which is a common source of confusion.
The second form adds a maleimide-bearing linker to the lysine at the carboxyl end. This group reacts with cysteine-34 on circulating serum albumin, forming a covalent bond that keeps the peptide in the bloodstream for far longer. ConjuChem developed the molecule as a way to extend the action of a peptide without frequent administration. The albumin attachment is the defining structural feature of the drug affinity complex version. Whether continuous exposure produces effects distinct from shorter pulses remains an unresolved research question.
| Property | Value | Notes |
|---|---|---|
| Molecular weight (no linker) | ~3.37 kDa | Calculated from peptide sequence |
| Molecular weight (with linker) | ~3.65 kDa | Includes albumin-binding moiety |
| Appearance | White to off-white powder | Typically lyophilized |
| Solubility | Soluble in water | Also dissolves in aqueous buffers |
| Common synonyms | Modified GRF(1-29), DAC:GRF | Usage varies by source |
Binding of the peptide to the growth hormone-releasing hormone receptor on pituitary somatotrophs triggers a G protein coupled cascade that raises cyclic AMP and opens calcium channels. The result is greater secretion of growth hormone into the bloodstream. Because the peptide acts at the same receptor as the natural hypothalamic hormone, its effect is amplified pulse size rather than an entirely separate release pathway. Receptor binding alone does not determine the response, since somatostatin tone and other inputs modulate the final output.
The albumin-binding version stays in circulation for days, because covalent attachment to serum albumin shields the peptide from rapid filtration and degradation. Reported half-lives for this form fall in the range of several days. The version without the linker is cleared in minutes, with estimates often near thirty minutes in animal work. These figures come from small studies and vary with assay method, species, and route, so they are best read as approximate rather than fixed constants.
Once in circulation, the peptide binds the growth hormone-releasing hormone receptor displayed on pituitary somatotroph cells. Receptor activation couples to Gs proteins, elevates intracellular cyclic AMP, and drives protein kinase A signaling inside the cell. That cascade increases discharge of growth hormone into the bloodstream. The analog therefore operates through a receptor pathway that already exists for the body's own releasing hormone, rather than through an engineered artificial target.
Clearance profiles diverge sharply between the two versions. The albumin-binding molecule stays in plasma for several days, whereas the unmodified analog is largely gone within about half an hour in reported work. Cleavage by dipeptidyl peptidase IV is a major contributor to the short life of the unmodified sequence. These gaps mean the two versions cannot be substituted for each other in study design or in reading results side by side.
The following binary (containing only two elements) technetium halides are known: TcF6, TcF5, TcCl4, TcBr4, TcBr3, α-TcCl3, β-TcCl3, TcI3, α-TcCl2, and β-TcCl2. The oxidation states range from Tc(VI) to Tc(II). Technetium halides exhibit different structure types, such as molecular octahedral complexes, extended chains, layered sheets, and metal clusters arranged in a three-dimensional network. These compounds are produced by combining the metal and halogen or by less direct reactions. TcCl4 is obtained by chlorination of Tc metal or Tc2O7. Upon heating, TcCl4 gives the corresponding Tc(III) and Tc(II) chlorides.
On 7 April, Trump announced that the US and Iran had reached an agreement based on the 10-point proposal mediated by Pakistani prime minister Shehbaz Sharif and Field Marshal Asim Munir. The US, Israel, and Iran agreed to a two-week ceasefire, under which Iran would re-open the Strait of Hormuz. After the announcement, Iran's Lavan Island oil refinery and Sirri Island crude export facilities were struck; no party claimed responsibility. In response, Iran continued missile and drone strikes on Gulf Arab states. The refinery attack was later revealed to have been done secretly by the UAE.
However, there are environmental concerns with this tanning method, as chromium is a heavy metal; while the trivalent chromium used for tanning is harmless, other byproducts can contain toxic variants. The method was developed in the latter half of the 19th century as tanneries wanted to find ways to speed up the process and to make leather more waterproof. Aldehyde-tanned leather is tanned using glutaraldehyde or oxazolidine compounds. It is referred to as "wet white" due to its pale cream color. It is the main type of "chrome-free" leather, often seen in shoes for infants and automobiles. Formaldehyde has been used for tanning in the past; it is being phased out due to danger to workers and sensitivity of many people to formaldehyde. Chamois leather is a form of aldehyde-tanned leather that is porous and highly water-absorbent. Chamois leather is made using oil (traditionally cod oil) that oxidizes to produce the aldehydes that tan the leather. Brain tanned leathers are made by a labor-intensive process that uses emulsified oils, often those of animal brains such as deer, cattle, and buffalo. An example of this kind is buckskin. Leather products made in this manner are known for their exceptional softness and washability. Alum leather is transformed using aluminium salts mixed with a variety of binders and protein sources, such as flour and egg yolk. Alum leather is not actually tanned; rather the process is called "tawing", and the resulting material reverts to rawhide if soaked in water long enough to remove the alum salts.
Sources: en.wikipedia.org
== Structure == Like other amino acids (not as a residue of a protein), cysteine exists as a zwitterion. Cysteine has l chirality in the older d/l notation based on homology to d- and l-glyceraldehyde. In the newer R/S system of designating chirality, based on the atomic numbers of atoms near the asymmetric carbon, cysteine (and selenocysteine) have R chirality, because of the presence of sulfur (or selenium) as a second neighbor to the asymmetric carbon atom. The remaining chiral amino acids, having lighter atoms in that position, have S chirality. Replacing sulfur with selenium gives selenocysteine.
=== Protein assembly === After initiation, elongation, and termination, there is a fourth step of the disassembly of the post-termination complex of ribosome, mRNA, and tRNA, which is a prerequisite for the next round of protein synthesis. The large ribosomal subunit has a role in protein folding both in vitro and in vivo. The large ribosomal subunit provides a hydrophobic surface for the hydrophobic collapse step of protein folding. The newly synthesized protein needs full access to the large subunit to fold; this process may take a period of time (5 minutes for beta-galactosidase).
Bromine is significantly less abundant in the crust than fluorine or chlorine, comprising only 2.5 parts per million of the Earth's crustal rocks, and then only as bromide salts. It is significantly more abundant in the oceans, resulting from long-term leaching. There, it makes up 65 parts per million, corresponding to a ratio of about one bromine atom for every 660 chlorine atoms. Salt lakes and brine wells may have higher bromine concentrations: for example, the Dead Sea contains 0.4% bromide ions. It is from these sources that bromine extraction is mostly economically feasible. Bromine is the tenth most abundant element in seawater. The main sources of bromine production are Israel and Jordan. The element is liberated by halogen exchange, using chlorine gas to oxidise Br− to Br2. This is then removed with a blast of steam or air, and is then condensed and purified. Today, bromine is transported in large-capacity metal drums or lead-lined tanks that can hold hundreds of kilograms or even tonnes of bromine. The bromine industry is about one-hundredth the size of the chlorine industry. Laboratory production is unnecessary because bromine is commercially available and has a long shelf life.
Sources: en.wikipedia.org
No. It is a synthetic analogue modeled on the first 29 residues of human GHRH. The substitutions and any linker are laboratory modifications rather than features of the endogenous peptide.
Early development used the albumin-binding form, and a shorter variant was later discussed under the same label. Because the two differ in half-life and handling, ambiguity arises whenever a source omits the variant designation.
The compound derives from that fragment but is not identical to it. The parent fragment lacks the stabilizing substitutions, so its degradation rate and duration of action differ noticeably.
Reported values cluster in the range of several days, reflecting slow release from the albumin complex. Estimates differ across species and assay platforms. The figure describes circulation time in study settings rather than a fixed property.